Health · 32 views
GLP-1-based meds are linked to fewer heart events in adults with obesity, autoimmune disease
Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac…
Summary
Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published in the Journal of the American Heart Association. This research was presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- 5 great cardio workouts you can do at homeContinue reading
- Supplement Shows Promise for Improving Cancer-Related Cognitive ImpairmentContinue reading
- Study identifies potential new treatment targets for the most common type of bowel cancerContinue reading
- STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclearContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow